Skip to main content
BC Innovations
Feature Story

Peripheral thinking in AD

How modulating Tregs could help treat AD

By Selina Koch, Staff Writer

Researchers at the Weizmann Institute of Science have shown for the first time that systemic immune suppression may contribute to neuroinflammation, brain pathology and cognitive dysfunction in Alzheimer's disease (AD), and that by taking the brakes off of peripheral immunity, companies may be able to develop therapies that recruit macrophages and T cells to treat the disease.

While the results only sketch the outline of the mechanism, they point to a central role for T regulatory cells (Tregs) in the process, making the cells a target for intervention.

Read Article

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.